

RESEARCH

Open Access

The paracrine effect of exogenous growth hormone alleviates dysmorphogenesis caused by *tbx5* deficiency in zebrafish (*Danio rerio*) embryos

Tzu-Chun Tsai^{1,2}, Jen-Kann Lu³, Sie-Lin Choo³, Shu-Yu Yeh³, Ren-Bing Tang^{2,4}, Hsin-Yu Lee⁵ and Jen-Her Lu^{2,4*}

Abstract

Background: Dysmorphogenesis and multiple organ defects are well known in zebrafish (*Danio rerio*) embryos with T-box transcription factor 5 (*tbx5*) deficiencies, mimicking human Holt-Oram syndrome.

Methods: Using an oligonucleotide-based microarray analysis to study the expression of special genes in *tbx5* morphants, we demonstrated that GH and some GH-related genes were markedly downregulated. Zebrafish embryos microinjected with *tbx5*-morpholino (MO) antisense RNA and mismatched antisense RNA in the 1-cell stage served as controls, while zebrafish embryos co-injected with exogenous growth hormone (GH) concomitant with *tbx5*-MO comprised the treatment group.

Results: The attenuating effects of GH in *tbx5*-MO knockdown embryos were quantified and observed at 24, 30, 48, 72, and 96 h post-fertilization. Though the understanding of mechanisms involving GH in the *tbx5* functioning complex is limited, exogenous GH supplied to *tbx5* knockdown zebrafish embryos is able to enhance the expression of downstream mediators in the GH and insulin-like growth factor (IGF)-1 pathway, including *igf1*, *ghra*, and *ghrb*, and signal transducers (*erk1*, *akt2*), and eventually to correct dysmorphogenesis in various organs including the heart and pectoral fins. Supplementary GH also reduced apoptosis as determined by a TUNEL assay and decreased the expression of apoptosis-related genes and proteins (*bcl2* and *bad*) according to semiquantitative reverse-transcription polymerase chain reaction and immunohistochemical analysis, respectively, as well as improving cell cycle-related genes (*p27* and *cdk2*) and cardiomyogenic genes (*amhc*, *vmhc*, and *cmlc2*).

Conclusions: Based on our results, *tbx5* knockdown causes a pseudo GH deficiency in zebrafish during early embryonic stages, and supplementation of exogenous GH can partially restore dysmorphogenesis, apoptosis, cell growth inhibition, and abnormal cardiomyogenesis in *tbx5* knockdown zebrafish in a paracrine manner.

Keywords: *tbx5*, Growth hormone, Apoptosis, Embryogenesis, Zebrafish

Background

T-box transcription factor 5 (TBX5) is essential for cardiogenesis and forelimb development during embryogenesis in vertebrates. Mutation or haploinsufficiency of *tbx5* in humans is related to Holt-Oram syndrome (HOS), which features congenital heart defects and forelimb deformities [1,2]. The TBX5 protein was proven to

be involved in determining early cell fate decisions, controlling differentiation and organogenesis, and regulating cardiac diastolic function in HOS patients [3,4]. In zebrafish, *tbx5* deficiency provokes cascading effects on multiple transcriptional expressions and causes extensive developmental retardation [5,6]. In developing zebrafish (*Danio rerio*) embryos, the *tbx5* gene is involved in the directed migration of individual lateral-plate mesodermal cells into future fin bud- and heart-producing regions [7], so embryos with the *tbx5* deficiency show anomalies in heart and pectoral fins that are identical to those in humans [6]. The *tbx5* deficiency also diminishes the expressions of *amhc/mhy6*, *vmhc*, and *cmlc2*, causes

* Correspondence: jklu@gmail.com

²School of Medicine, National Yang Ming University, Taipei, Taiwan, Republic of China

⁴Department of Pediatrics, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China

Full list of author information is available at the end of the article

heart defects, and is associated with pectoral fin anomalies and developmental delays [8,9]. Furthermore, TBX5 regulates organogenesis by modifying the activities of many transcription factors [8,10-12].

Tbx5 also has essential roles in regulating progression of the cell cycle [13], cell growth, and apoptosis [14]. Blocking cell-cycle progression by *tbx5* depletion at the RNA level leads to a decrease in the cardiac cell number, an alteration in the timing of the cardiac differentiation program, defects in cardiac sarcomere formation, and ultimately cardiac programmed cell death [13,15].

GH belongs to the GH/prolactin (PRL) superfamily and functions by binding to homodimeric GH receptors. It is the major regulator of growth and is an important metabolic hormone [16]. Recent studies established that the GH/PRL superfamily is essential for organogenesis, such as that of the head, eyes, melanophores, and gas bladder in zebrafish [4]. Besides being implicated in growth, GH regulates gonad development, osmoregulation, and immunity in fish as well [17]. In GH-transgenic zebrafish, the overexpression of GH reduced the transcription of the antioxidant defense system and myogenesis-related genes [18], although the consequences of a shortage of GH in zebrafish embryos remain unknown.

Because the gain and loss of functions of GH in embryos cause developmental defects, GH is thought to play a vital role in embryogenesis. GH participates in embryonic development as a growth and differentiation factor, and in cell proliferation as an antiapoptotic factor and in meiotic progression [19,20]. Instead of pituitary GH, maternal or local GH takes part in regulating early embryogenesis *via* paracrine/autocrine effects, since GH and its receptors exist prior to the formation of functional pituitary somatotrophs [21,22].

Even though there is no evidence to date that shows any interaction between TBX5 and GH, both of them work with allied functions in regulating apoptosis, the cell cycle, and myogenesis during embryogenesis. Therefore, the role of GH during embryogenesis in embryos with congenital defects caused by an insufficiency of TBX5 remains undetermined but significant. In our study, GH was microinjected into zebrafish embryos at the 1~4-cell stages to reveal paracrine restoration effects from exogenous GH in *tbx5* morphants.

Methods

Animal ethics statement

Approval of this experiment was permitted by the Animal Ethics Review Board of National Taiwan Ocean University Aquaculture. Since zebrafish embryo under 7 day (168 hour post-fertilization) is excluded in the definition of "vertebrate animal" in review board, our study which used zebrafish embryo under 48 hpf was spared of

regulation and review process of Basic Institutional Review Board (IRB).

Maintenance of zebrafish

Zebrafish were maintained in 45-L aquaria heated to 28.5 °C with 25 fish per tank. The water was filtered, and about half of the water was replaced at least once a week. Adult zebrafish were fed 1 or 2 times per day with a variety of food, and the tank was cleaned by siphoning off any excess food after the second daily feeding. The day-night cycle was controlled with an automatic timer (14 h of light/10 h of dark).

Breeding of zebrafish

Zebrafish reach sexual maturity in 10~12 weeks, but breeding fish should be 7~18 months of age for maximum embryo production. The day before breeding, 1/3 of the water was replaced and the tank was cleaned after feeding (1~2 h before the end of the light period). Finally, a collection box was placed at the bottom of the tank, and preparations were made to collect the embryos the next day.

Embryo collection

We removed the collection box in the morning when the light was turned on and placed the collected embryos into an incubator maintained at a temperature of 28.5 °C.

RNA isolation

Total RNA was isolated from 50 embryos using the guanidine isothiocyanate-based TRIzol solution. RNA samples were re-suspended in DEPC-treated water and quantified spectrophotometrically at 260 nm. The RNA quality was then checked by 1.2 % agarose gel electrophoresis, after staining with 1 µg/ml ethidium bromide. The RNA stock solution was stored at -80 °C.

Microarray

Isolated total zebrafish embryo RNA was purified using an RNeasy[®] Mini Kit (QIAGEN, Hilden, Germany), and the quality was confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Cruz, CA, USA). Purified RNA was reverse-transcribed into complementary (c)DNA using SuperScrip TM III RT (Invitrogen, Carlsbad, CA, USA). Before purifying and coupling the fluorescent dye using indirect cDNA labeling with a microarray kit (Invitrogen), the cDNA was hydrolyzed and neutralized using NaOH and HCl. The cDNA was then pretreated with GEx hybridization buffer (HI-PRM; Agilent Technologies) before transferring to hybridization chamber gasket slides for the hybridization reaction. The slide was scanned with an Axon Instruments GenePix 4000B scanner (Molecular Devices, Silicon Valley, CA,

USA) and data analyzed with Genespring GX 10.0.2 (Agilent Technologies). All data is MIAME compliant and the raw data has been deposited in a GEO database (GSE33965) [NCBI tracking system #16217606].

Semiquantitative reverse-transcriptase polymerase chain reaction (RT-PCR)

Total RNA was prepared from 50 defective or normal embryos (Invitrogen), with amplification of 3 µl of 1st-strand cDNA. Amplification primers for each specific mRNA deduced from published sequences were *igf1* (P1: 5'-TCTCATCTCTTTCTCGC-3', P2: 5'-GATAGTTTCTGCCCC-3'), *ghra* (P1: 5'-AAGCATTGAGAGGTG-3', P2: 5'-AGAGGAAGTGAGGAGAA-3'), *ghrb* (P1: 5'-GTTCCACCCGTTTTCA-3', P2: 5'-GCGAGTCCTCAT-TCTGT-3'), *akt2* (P1: 5'-GAAGAGGATGAGCCAATG-3' and P2: 5'-CTCCAACGCTGAAACAAT-3'), and *erk1* (P1: 5'-TCTGCCAATGTGCTGC-3', P2: 5'-TGCCGTCCTCAAAG-3'). PCR conditions were comprised of denaturation at 95 °C for 3 min followed by 50 cycles of amplification (95 °C for 20 s, 59 °C for 15 s, and 72 °C for 20 s).

Microinjection and morpholino (MO) treatment

The MO antisense oligonucleotide, *tbx5*-MO (5-GAA-AGGTGTCTTCACTGTCCGCCAT-3), was designed against the *tbx5* translational start site (Gene Tools, Philomath, OR, USA). Wild-type (WT) embryos, primarily at the 1-cell stage with the chorion intact, were injected with 19.4 ng/4.3 nl of stock MO diluted in Danieau's solution. Injected embryos were raised at 28.5 °C. Embryos used for analyzing the expression of various markers were fixed with 4 % paraformaldehyde. Otherwise, embryos were scored after 2 days of development for late effects. In our previous study, 4 control groups, including the 3' end of *tbx5*-MO(2) (5'-GCCTGTACGATGTCTACCGTGAGGC-3'), mismatched *tbx5*-MO (5'-GTCTCTTGACTCTCCGCGATCTCGG-3'), and embryos with blank microinjection and wild-types without microinjection, were included to identify the specific blockage of *tbx5* mRNA translation effect of *tbx5*-MO [9]. The efficacy and specificity of the *tbx5*-MO has been confirmed in previous published articles [9,14].

Exogenous treatment with GH

Zebrafish embryos were micro-injected with 1 fM of human GH (Sigma-Aldrich, St. Louis, MO, USA) ($n = 150$ /group, with triplicate determinations), accompanied by 19.4 ng/2.3 nl *tbx5*-MO at the 1-cell stage. Treated zebrafish embryos were placed into plates with wells, and their functional classification was evaluated at 30, 48, 72, and 96 h post-fertilization (hpf).

Normal morphological growth rate assessment

Treated zebrafish embryos were placed into a plate with wells for longitudinal follow-up at 12 ~ 18-h intervals. The normal morphological growth rate was evaluated at 24, 30, and 48 hpf.

Whole-mount *in situ* hybridization

Whole-mount *in situ* hybridization was performed as previously described by Schulte-Merker et al. [23]. The digoxigenin-labeled antisense full-length *amhc*, *vmhc*, and *cmlc2* RNA probes were transcribed using T7 RNA polymerase (Promega, Madison, WI, USA). Whole-mount *in situ* hybridization was carried out essentially as described by Oxtoby and Jowett [24]. In brief, embryos were fixed with 4 % paraformaldehyde, digested with proteinase K, and hybridized with the zebrafish *amhc*, *vmhc*, or *cmlc2* probes at 67 °C. An alkaline phosphatase-conjugated anti-digoxigenin antibody (Boehringer Mannheim, Dassel, Germany) was used to detect zebrafish *amhc*, *vmhc*, or *cmlc2* signals. After staining with NBT/BCIP (Boehringer Mannheim), embryos were re-fixed with 4 % paraformaldehyde and stored in phosphate-buffered saline (PBS).

Immunohistochemical analysis

Zebrafish embryos were fixed with 4 % paraformaldehyde in PBS. De-paraffinized sections (3 µm) of zebrafish embryo tissues were placed on slides and processed for immunohistochemistry. After application of a biotin blocking system (Dako, Glostrup, Denmark) for 30 min, sections were incubated with target-purified rabbit primary antibodies, including Bcl2, Bad, Cdk2, and P27 (all from Anaspec, Fremont, CA, USA) washed in PBS, and then incubated with a rhodamine-conjugated secondary antibody, goat anti-rabbit immunoglobulin G (IgG). After washing in PBS, sections were incubated with mounting medium and kept at 4 °C.

Transmission electron microscopic (TEM) examinations

Embryos were fixed at 48 hpf with 2.5 % glutaraldehyde in Sorenson's phosphate buffer, post-fixed with 1 % OsO₄ in Sorenson's phosphate buffer followed by dehydration through a graded series of ethanol washes, and embedded in Spurr's EPON. Blocks were heated in an oven for 8 h at 70 °C. Semi-thin (1 µm) sections were cut and stained with toluidine blue for adequate preview under a microscope. Ultrathin sections (900 Å) were cut with a diamond knife, stained with uranyl acetate and lead citrate, and examined with an electron microscope.

TdT-UTP nick end labeling (TUNEL) assay

Both whole mount and sectioned TUNEL assays were performed using an ApopTag kit (Chemicon, Heule, Belgium). Zebrafish embryos were briefly fixed with 4 %

paraformaldehyde in PBS. Proteinase K-treated whole embryos or de-paraffinized sections (5 μ m) of embryos were incubated with the TdT enzyme followed by anti-digoxigenin. Finally, embryos or slides were stained with DAB for 5 min.

Western blot analysis

Embryos were homogenized on ice in lysis buffer (Sigma-Aldrich). Cellular debris was then pelletized by centrifugation at 12,000 rpm for 20 min, and the supernatant was collected and measured. Proteins were mixed with sample buffer before separation in 10 % sodium dodecyl-sulfate polyacrylamide electrophoresis (SDS-PAGE) gels. The SDS-PAGE was then transferred onto nitrocellulose membranes at 100 V for 1 h. Membranes were blocked with 5 % bovine serum albumin (BSA) buffer at room temperature for 1 h. The Akt and Erk primary antibody (Aviva Systems Biology, San Diego, CA, USA) was incubated overnight at 4 °C at a dilution of 1:1000. Nitrocellulose membranes were washed with PBST followed by incubation with a horseradish peroxidase (HRP)-conjugated secondary antibody (1:5000) for 1 h at room temperature before the images were digitized.

Statistical analysis

Results are given as the mean \pm S.D. Where applicable, Duncan's new multiple range test was used to compare every pair of testing groups. Statistical significance was accepted at $p < 0.05$.

Results

The *tbx5* insufficiency causes morphological changes during zebrafish embryonic development

At 48 hpf, looped hearts with apparent chambers (atria and ventricle) were observed in WT zebrafish embryos (Figure 1A), their trunks appeared straight without bending, and somites were "V-shaped" (Figure 1F). At 96 hpf, they displayed well-formed pairs of pectoral fins (Figure 1K). Perturbations of cardiac development (Figure 1B) were exhibited in *tbx5*-MO treated (MO) zebrafish embryos, along with curved trunks and abnormal "U-shaped" somites (Figure 1G), and pectoral fin growth (Figure 1L) was either truncated or even atretic. Moreover, the defect rates in the heart (Figure 1P), trunk (Figure 1Q), and pectoral fins (Figure 1R) were very high in the MO group compared to those of the WT and mismatch *tbx5*-MO-treated (MIS) groups. Formation of the heart (Figure 1C), trunk (Figure 1H), and pectoral fins (Figure 1M) in the MIS and WT groups was similar.

Multiple growth-related genes were downregulated in *tbx5* knockdown embryos

We screened growth-related genes that were downregulated after knockdown of *tbx5* using a zebrafish microarray.

Genes that were 1.5 \times downregulated were included. Multiple genes participating in growth were downregulated in zebrafish embryos with the *tbx5* deficiency (Table 1). Growth-related genes *igfbp2b*, *ghra*, *ing4*, *mdkb*, *grb2*, *vegfaa*, and *fbp1* were downregulated at the heart-tube stage at 24 hpf. At 30 hpf, when the heart begins to loop, *pdgfab*, *gh1*, *fgf1*, *fgf6a*, and *vegfab* were downregulated in *tbx5* knockdown embryos. Furthermore, *gata5* and *ghr1* were found to be downregulated at 48 hpf.

Exogenous GH-improved embryonic defects in zebrafish with *tbx5* deficiency

Data from microarray screening showed that GH was downregulated in the early embryonic stages in zebrafish embryos with the *tbx5* deficiency. WT embryos did not show defects of the heart (Figure 1P), pectoral fins (Figure 1Q), or trunk (Figure 1R). Microinjection of GH into *tbx5*-MO treated embryos (MOGH group) caused defects of the heart (22.7 % at 24 hpf, 37.3 % at 30 hpf, and 46.7 % at 48 hpf; Figure 1P), pectoral fins (61.3 % at 24 hpf, 64.7 % at 30 hpf, and 65.3 % at 48 hpf; Figure 1Q), and trunk (45.3 % at 24 hpf, 45.3 % at 30 hpf, and 46.7 % at 48 hpf; Figure 1R).

Microinjection of *tbx5*-MO into WT embryos (the MO group) caused specific defects of the heart (string-like heart, cardiac edema, and loss of ventricular contractility) (51.3 % at 24 hpf, 74.7 % at 30 hpf, and 96 % at 48 hpf; Figure 1P), pectoral fins (85.3 % at 24 hpf, 88 % at 30 hpf, and 88 % at 48 hpf; Figure 1Q), and trunk (76 % at 24 hpf, 80 % at 30 hpf, and 78.7 % at 48 hpf; Figure 1R). Comparing the MO group to the MOGH group, the incidence of embryonic defects due to *tbx5* insufficiency was significantly reduced (Figure 1P-R).

Compared to the WT group, microinjection of exogenous GH into WT embryos (WTGH) did not cause significant phenotypic changes, and no embryonic defects were identified (Figure 1P-R). There were no statistical differences in embryonic defects between the WT group ($n = 50$) and either the MIS group ($n = 50$) or the WTGH group ($n = 50$).

The paracrinous effect of exogenous GH in activating the IGF-1 pathway

Genes participating in the GH/IGF-1 pathways, *igf1* (Figure 2A), *ghra* (Figure 2B), and *ghrb* (Figure 2C), were downregulated in the MO group but were partly reactivated in the study groups simultaneously treated with GH (Figure 2A-C). On the other hand, genes participating in the GH/IGF-1 pathway showed no statistically significant differences in the WT group and MIS group (Figure 2A, B, C).

Since the affected receptors function through phosphorylation, we examined the expression of phosphorylation-related genes, *erk1* and *akt2*, at the protein and gene levels




Table 1 1.5x down regulated growth -related genes in *tbx5* knockdown embryos in different embryonic developmental stages

Gene Symbol	Gene Name	Genbank #	Function	Stage (hpf)	Reference
<i>igfbp2b</i>	insulin-like growth factor protein 2b	NM_131458	general embryonic development and growth, regulating vascular development	24	Zhou, 2008
<i>ghra</i>	growth hormone receptor a	NM_001083578	cytokine receptor activity	24	Di Prinzio, 2010
<i>ing4</i>	inhibitor of growth family, member 4	NM_001020468	regulating brain tumour growth and angiogenesis	24	Susan Nozell, 2008
<i>mdkb</i>	midkine-related growth factor b	NM_131716	brain development, neural crest formation	24	Liedtke, 2008
<i>grb2</i>	growth factor receptor-bound protein 2	NM_213035	distinct effects on neural crest and floorplate development	24	Ryan P Million, 2004
<i>vegfaa</i>	vascular endothelial growth factor Aa	AF016244	blood vessel endothelial cell proliferation	24	Bahary, 2007
<i>fibpl</i>	fibroblast growth factor (acidic) intracellular binding protein, like	NM_212861	Kupffer's vesicle development	24	Hong, 2009
<i>pdgfab</i>	platelet derived growth factor alpha b	NM_001076757	positive regulation of cell division	30	Eberhart, 2008
<i>gh1</i>	growth hormone 1	NM_001020492	growth control	30	Toro, 2009
<i>fgf1</i>	fibroblast growth factor 1	NM_200760	hemopoiesis	30	Songhet, 2007
<i>vegfab</i>	vascular endothelial growth factor Ab	NM_001044855	angiogenesis	30	Bahary, 2007
<i>gata5</i>	GATA-binding protein 5	NM_131235	specification of cardiomyocytes	48	Holtzinger, 2007
<i>ghrl</i>	ghrelin/obestatin preprohormone	NM_001083872.1	encodes ghrelin-obestatin preproprotein	48	Li, 2009

using Western blot and semiquantitative RT-PCR, respectively. Gene expression levels of *erk1* (Figure 2E) and *akt2* (Figure 2F) could be identified at 24, 30, and 48 hpf, but were depressed in embryos with the *tbx5* deficiency. Exogenous GH increased the expression of genes and proteins in embryos with the *tbx5* deficiency, but these expressions caused no significant changes in the MIS group (Figure 2E, F). GH downstream factors Erk and Akt, however, were significantly reduced in the MO group, and their gene expressions were improved in the MOGH group.

Expressions of the phosphorylation-related genes of *erk1* and *akt2* in the WT, MIS, and WTGH microinjection groups were similar (Figure 2D-F).

Exogenous GH partially normalized the apoptotic effect induced by *tbx5* deficiency

The TUNEL assay demonstrated only few apoptotic spots in WT (Figure 3A), MIS (Figure 3B), and WTGH embryos (Figure 3C). Apoptotic spots were significantly induced in the MO group (Figure 3D) and were diminished in the MOGH-treated group (Figure 3E).

We analyzed the expressions of cell apoptosis-related genes at the RNA and protein levels. Our results showed a remarkable increase of *bcl2* (Figure 4A) and *bad*

(Figure 4B) in MO group embryos in all studied periods. However, compared to gene expression in the WT group, no significant changes were found in embryos injected with either MIS or WTGH (Figure 5A, B). Overexpression of the *bad* and *bcl2* genes was then confirmed by analyzing their protein expressions by performing immunohistochemical analyses in the heart and pectoral fins at 30 hpf. Bad and Bcl2 genes showed identical protein expression patterns, which were observed in messenger (m) RNA expression analysis in the heart and pectoral fins (Figure 4C-R). Mild expressions of the apoptosis-related proteins, Bad and Bcl2, were observed in the heart (Figure 4C, G) and pectoral fins (Figure 4K, 4O) of WT embryos, and increased expressions of Bad and Bcl2 were detected in the heart (Figure 4E, I) and pectoral fins (Figure 4M, Q) of *tbx5* knockdown embryos. Expression levels of apoptosis-related proteins were observed in the heart (Figure 4D, F, H, J) and pectoral fins (Figure. 4L, N, P, R) of the WTGH and MOGH groups.

Effect of exogenous GH on genes related to the cell cycle

Depletion of *tbx5* caused an increase in the expressions of S stage-related mRNA *p27* and *cdk2* (Figure 5A, B) in *tbx5* morphants. However, in the MOGH group, expressions of *p27* and *cdk2* were partially restored, which




Figure 2 Expressions of *igf1*, *ghra*, *ghrb*, *akt2*, and *erk1* in *tbx5* knockdown embryos. (A) The expression of *igf1* was significantly reduced in MO group embryos throughout the developmental stages. Its expression in WTGH and MIS embryos was similar to the control and wild-type (WT) groups. The expression of *igf1* was significantly restored in the WTGH treatment group. Expressions of GH receptors *ghra* (B) and *ghrb* (C) were significantly depressed in MO embryos but restored in the MOGH treatment group. (D) In the Western blot analysis, protein expressions of Akt and Erk in MO zebrafish embryos were depressed, but expressions were similar among the WT, MIS, and WTGH groups at 30 h post-fertilization (hpf). Expressions of Akt and Erk were restored in the MOGH group. In the semiquantitative PCR analysis, mRNA expressions of *erk1* (E) and *akt2* (F) were significantly reduced in MO group embryos and restored in the MOGH group. Data are presented as the mean \pm S.D. * $p < 0.05$ vs. WT; # $p < 0.05$ MOGH vs. MO. MO, *tbx5* knockdown; MIS, mismatched *tbx5*-MO-treated embryos; WTGH, WT embryos treated with growth hormone (GH); MOGH, *tbx5*-MO- and GH-treated embryos.


showed no significant difference compared to the WT or MIS groups (Figure 5A, B).

mRNA expressions of cell cycle-related genes were confirmed by performing an immunohistochemical analysis. Protein expressions of Cdk2 and P27 in the heart and pectoral fins had similar patterns as observed in the mRNA expression analysis (Figure 5C-R). Expressions of cell cycle-related proteins, Cdk2 and P27, were observed in the heart (Figure. 5C, G) and pectoral fins (Figure 5K, O) of WT embryos. Expressions of Cdk2 and P27 were

induced in the heart (Figure. 5E, I) and pectoral fins (Figure 5M, Q) of MO-group embryos. Protein expression levels of Cdk2 and P27 were identical in the heart (Figure 5D, 5 E, 5 H, 5 J) and pectoral fins (Figure 5L, N, P, R) of the WTGH and MOGH groups.

Exogenous GH improves the expression of cardiomyogenesis genes in *tbx5* knockdown embryos

The result of whole-mount *in situ* hybridization demonstrated that the expressions of *amhc*, *vmhc*, and *cmlc2*




were reduced in *tbx5* knockdown embryos (Figure 6G-I) compared to WT embryos (Figure 6D-F); however, in the MOGH group, expressions of *amhc* (Figure. 6J),

vmhc (Figure 6K), and *cmlc2* (Figure 6L) were improved. In a semiquantitative RT-PCR test, the expression of *amhc* was repressed at 48 hpf in the MO group and was improved in the MOGH treatment group (Figure 6A). On the other hand, expressions of *vmhc* (Figure 6B) and *cmlc2* (Figure 6C) were significantly repressed in all developmental stages in *tbx5* knockdown embryos but were significantly improved in the MOGH-treated group. Their expressions in the MIS, WTGH, and WT groups were similar (Figure 6A-C).

Discussion

Significant dysmorphogenesis (Figure 1) shown in the MO group is similar to congenital defects in humans with HOS. The defects of a string heart [6,10,11,15,25-29] and dysgenetic fins [30-32] are well studied in several species models with *tbx5* insufficiency, especially zebrafish. We also explored those genes associated with altered *tbx5* levels during embryogenesis and those which contribute to developmental defects. We investigated gene expressions in dysmorphogenesis of a zebrafish *tbx5*-deficient model in order to reveal the role of *tbx5* in altering transcription using an oligonucleotide-based microarray analysis, as it is sensitive to a single injection of *tbx5* morpholino in zebrafish embryos. Our microarray analysis results identified many genes with different functions and different categories that were up- or downregulated in zebrafish embryos with *tbx5* deficiency by morpholino in the early stages of organogenesis. Among these genes, some associated with growth, including *igf1b2b*, *gh1*, *ghr1*, and *ghra*, which occur respectively during different time windows of embryogenesis and are normally activated during different stages of early organogenesis, were appreciably depressed in embryos with *tbx5* deficiency [32-35]. A deficiency in *tbx5* leads to multiple organ defects including the heart, trunk, and pectoral fins, and also decreases the expressions of *gh1* (*gh*), and *ghra* [32,36]. Our data also revealed that knockdown of *tbx5* in embryos diminished GH/IGF-1 pathway mediators, including GH, IGF-1, and GH receptors.


Exogenous GH was used in our study to partially restore the anomalies during embryogenesis to ensure the involvement of GH in multiple organ defects by *tbx5* knockdown. In the study, we injected human recombinant GH, which human GH instead of zebrafish GH is reported to have full activity in fish as well as in human [37], into the yolk of the zebrafish embryos as an alternative of soaking the embryos with GH-containing water. Partially because the GH containing water solution is difficult to control the concentration, partially microinjection remains the most effective methods to introduce DNA, RNA, and proteins into fertilized zebrafish eggs and embryos [38]. Theoretically, the recombinant



GH could be successfully delivered into the yolk of 1–2 cell stages and diffused into most embryonic cells of blastomere *via* intercellular substance. The expression of *igf1*, *ghra*, *ghrb*, *erk1*, and *akt2* genes was increasing after co-injection with GH and *tbx5* morpholino at 1-cell stage. These results revealed the exogenous GH has activated the downstream signaling pathway. However, it is still unknown how and where the exogenous GH binds with the GH receptors. Whether the injected exogenous human GH is packaged and sent outward to bind with

the membranous GH receptors, or it directly binds with the cytoplasmic GH receptors, remains unidentified because the expression of GH receptors could be either in the nucleus or cytoplasm, or both, in different embryonic tissues and cells [39].


Exogenous GH in zebrafish embryos with *tbx5* deficiency could activate expression of GH receptor genes, to induce an increase in *igf1* levels, and to elevate downstream Akt and Erk systems, coinciding with restoration of morphological anomalies and transcriptional cascades.



It could be hypothesized that GH is a factor that may act in a paracrine manner within the *tbx5* functional pathway to modulate embryonic development.

Tbx5 is essential for regulating the progression of the cell cycle by controlling the length of the embryonic cardiac cell cycle [13] and regulating apoptosis in endocardial cells, myocardial cells and the *septum primum* [40], all of which contribute to abnormal cardiogenesis. GH influences the growth of embryonic cells and modulates embryo cell cycle and proapoptotic metabolism [41]. In

our study, exogenous GH partially restored the expression of *tbx5* downregulated genes, which contributes to developmental delays in organogenesis including the cell cycle (*p27* and *cdk2*) and apoptosis (*bcl2* and *bad*). Early administration of exogenous GH improves the outcome of *tbx5*-deficiency-mediated heart defect embryos probably by inducing cardiac cells to re-enter the cell cycle. It also reduces aberrant apoptosis because GH works in a similar way to stimulate the cardiomyocyte to re-enter the cell cycle and thereby increases the number of



cardiac myocytes in ischemic and infarcted myocardia [3,26].

The GH signaling pathway governs cell growth, proliferation, and apoptosis by controlling key regulatory genes that execute these processes. Herein, we also provide the first evidence that *tbx5* acts together with GH to regulate cardiac myogenetic pathway-responsive genes (*cmc2*, *amhc*, and *vmhc*). Exogenous GH restored the expression levels of *amhc*, *vmhc*, and *cmc2* in our *tbx5* morphant embryos with cardiac defects. Inactivation of *tbx5* diminished *amhc*, *vmhc*, and *cmc2* expressions, and although it also reduced heart size, exogenous GH reversed that result and enhanced cardiac formation in zebrafish embryos. Our results indicate not only that GH is necessary for the growth of these cardiac structures, but also that supplementary exogenous GH restores *tbx5* knockdown-mediated defects, including dysmorphogenesis and cardiomyogenesis, via cell proliferative and apoptotic pathways. It could be concluded that knockdown of *tbx5* in early zebrafish embryogenesis causes functional GH deficiency and leads to dysmorphogenesis.

The comorbidity of morphologic defects and functional GH deficiency could be observed in early embryogenesis of *tbx5* morphants and implied that GH may involve a role in embryogenesis including cardiomyogenesis through transcriptional regulation of *tbx5*.

We found no literature underlining the interaction or the relationship between *tbx5* and growth-related genes shown in Table 1. This is especially true for GH. TBX5 is a member of the T-box transcription factor family. It has a sequence-specific DNA-binding site that improves an inducible recognition element of TBX5 that binds to a specific DNA sequence [42]. Thus, *tbx5* synergistically activates transcriptional regulation of downstream gene expression and controls the transcription of genetic information in embryonic development. In many *tbx5* mutants, affinities bound to a specific DNA target site were reduced by a variable amount, and even the ability to bind nonspecific DNA differs. Both contribute to the misregulation of target gene expression.

GH exerts different actions in different tissues through a complex functioning pathway involving many growth

factors and their receptors [43]. It is mainly supposed to act through mediation of the GH/IGF-1 pathway, including GH receptors and cytoplasmic and intranuclear factors. Though the relationship between *tbx5* and GH remains undetermined, there exist some interactions or association between them during zebrafish embryogenesis. According to the recent studies, we could reasonably assume that transcription factors, probably including TBX5, may play a role in interacting with the GH mediator array in the nucleus. For example, GH-responsive transcription factors in sex-specific liver gene expressions are an example of interaction between GH and transcription factors in specific tissues [44]. Meanwhile, a transcription factor that regulates GH-variant gene expression could also exist [45]. On the other hand, the latest investigation declared, the transcription factor STAT3 (signal transducer and activator of transcription 3), one of downstream signaling molecules for GH, directly control the expression of *tbx5* in P19CL6 cells for cardiomyocyte differentiation [46]. The conclusion not only points out a connection between GH and TBX5 transcription factor, but also implies that GH might activate and increase *tbx5* expression in *tbx5* morphants. That is, GH compensates the deficiency of TBX5 via STAT3 and other transcriptional factors and maintains the *tbx5*-associated cascade effects of organogenesis and morphogenesis in early embryonic stages, partially.

Though GH is generally considered to be an endocrine factor because it is primarily synthesized by pituitary somatotrophs and is secreted into the circulation. However, it has been clear that GH is produced in many tissues outside the pituitary gland and acts as a local or maternal growth factor in the autocrine/paracrine regulation of cellular differentiation during embryonic and fetal development [22,47]. Because the growth effect occurs prior to differentiation of pituitary somatotrophs, early embryonic growth is independent of pituitary GH. Prinzi *et al.* announces the distribution and expression of growth hormone receptors, *ghra* and *ghrb*, in embryonic zebrafish by means of RT-PCR and whole mount *in situ* hybridization, and the genomic organization by cloning and sequence analysis [32]. They prove *ghra* and *ghrb* expression was detected at all stages entail maternal origin [32]. It is undeniable that maternal GH did play a role in early embryonic development of zebrafish; and it is taken for granted that blockage of GH directly interferes with normal cardiac development and even induces cardiac malformation and dysfunction [48]. If we hypothesized that Tbx5 may play a role in interaction with maternal/local GH and in the activation of cascade GH signaling in early embryonic development to assist the chronological organogenesis. Then it is reasonable that the normal physical responses to maternal GH in embryonic zebrafish development is decreased after

knockdown of *tbx5*, and the responses could be reinforced by extra supplement of passable exogenous GH.

Phosphorylation that is mediated by PI3K-AKT and MAPK signaling cascades is an important component of the acting mechanism of local GH-stimulated transcription at the organogenesis phase [49-51]. Our results suggest that the local GH pathway acts similarly to the conventional GH/IGF-1 signaling pathway [48,52-54] and that exogenous GH activates Akt and Erk pathways in the nucleus, probably by binding to local insulin receptors. Local GH signaling downstream of the PI3K-AKT system is a key effect related to regulation of cell survival and mRNA translation, while signaling downstream of the MAPK-ERK system involves regulating cellular proliferation. This suggests that exogenous GH signaling occurs *via* local GH receptors during heart looping formation and chamber maturation stages.

We established four control groups in order to verify the specific GH effects without interference of morpholino and technical influences of micro-injection. However, interesting phenomena were disclosed by careful interpretation among those different control groups. First, *igf1* transiently surged in zebrafish embryos injected by missense morpholino (MISMO group) without subsequent effects, but the phenomenon didn't happen in the expressions of *ghra*, *ghrb*, *erk1*, and *akt2*. It may aggressively assume that GH effects may involve IGF-1 dependent and independent pathways in embryonic development to switch on the cascade reactions. Thus the role of IGF-1 attracts attention for further exploration. Moreover, the expressions of *ghra* and *ghrb* in WTGH group significantly increased than MOGH group, but the expressions of *erk1*, *akt2*, *amhc*, *vmhc*, *cmlc2* in WTGH group had no remarkable change than MOGH group. It implies that excess GH works inefficiently in individuals without *tbx5* deficiency, or GH deficiency. GH receptors could be reactivated and responded to exogenous GH, but downstream signals and cardiomyogenesis-related genes didn't markedly act in response to overload of GH. The results are compatible with the biological functions of GH in mature adult individuals. Surly, supplementary designs of control groups, for example, such as use of BSA with equivalent amount as a blank control, could be launched to access the authentic GH effects by our experimental model.

Although GH is able to partially restore dysmorphogenesis and cascade gene expressions in *tbx5* morphants, it cannot completely rescue those changes. Proper timing of GH treatment and optimal dosing might be found to enhance its therapeutic capability. Conversely, this approach may be limited by GH being partially significant to the complex functioning of the *tbx5* network or because it compensates for only a small part of the chronological effects of *tbx5* deficiency. Additional

research is required to determine whether it is practicable to introduce GH to mend developmental defects in early embryogenesis.

Conclusions

In summary, our work provides novel insights into the possible role of GH in contributing to developmental defects in zebrafish embryos with *tbx5* deficiency. We suggest that the functional knockdown of zebrafish *tbx5* results in a failure to develop a complete or functional heart, trunk, and pectoral fins and might be due to a functional GH deficiency induced by the *tbx5* deficiency because it is a key factor causing abnormal organogenesis. Exogenous GH experiments in zebrafish embryos with *tbx5* deficiency led to the conclusion that intrinsic growth-control mechanisms, including apoptosis, cell cycle, and cardiomyogenesis that control organic growth, depend on local GH and growth factors between cells and their neighbors. They also indicate that these interactions include controlling cardiac loop formation and the development of trunk and pectoral fins. The improvement of abnormal embryonic organogenesis in zebrafish embryos with *tbx5* deficiency by the administration of exogenous GH suggests its potential application in human congenital anomalies.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Medical Research and Education, National Yang-Ming University Hospital, Yilan, Taiwan, Republic of China. ²School of Medicine, National Yang Ming University, Taipei, Taiwan, Republic of China. ³Laboratory of Molecular Biology, Institute of Aquaculture, National Taiwan Ocean University, Keelung, Taiwan, Republic of China. ⁴Department of Pediatrics, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China. ⁵Institute of Zoology, National Taiwan University, Taipei, Taiwan, Republic of China.

Authors' contributions

JHL and JKL conceived of the study, participated in its design, coordination. TCT participated in its design and drafted the manuscript. SLC and SYY carried out the molecular genetic studies. RBT and HYL participated in its design and coordination. All authors read and approved the final manuscript.

Received: 7 February 2012 Accepted: 9 July 2012

Published: 9 July 2012

References

1. Basson CT, Bachinsky DR, Lin RC, Levi T, Elkins JA, Soultz J, Grayzel D, Kroumpouzou E, Traill TA, Leblanc-Stracessi J, Renault B, Kucherlapati R, Seidman JG, Seidman CE: **Mutations in human TBX5 cause limb and cardiac malformation in Holt-Oram syndrome.** *Nat Genet* 1997, **15**:30–35.
2. Li QY, Newbury-Ecob RA, Terrett JA, Wilson DI, Curtis AR, Yi CH, Gebuhr T, Bullen PJ, Robson SC, Strachan T, Bonnet D, Lyonnet S, Young ID, Raeburn JA, Buckler AJ, Law DJ, Brook JD: **Holt-Oram syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene family.** *Nat Genet* 1997, **15**:21–29.
3. Hatcher CJ, Diman NY, Kim MS, Pennisi D, Song Y, Goldstein MM, Mikawa T, Basson CT: **A role for Tbx5 in proepicardial cell migration during cardiogenesis.** *Physiol Genomics* 2004, **18**:129–140.
4. Zhu Y, Song D, Tran NT, Nguyen N: **The effects of the members of growth hormone family knockdown in zebrafish development.** *Gen Comp Endocrinol* 2007, **150**:395–404.
5. Begemann G, Ingham PW: **Developmental regulation of Tbx5 in zebrafish embryogenesis.** *Mech Dev* 2000, **90**:299–304.
6. Garrity DM, Childs S, Fishman MC: **The heartstrings mutation in zebrafish causes heart/fin Tbx5 deficiency syndrome.** *Development* 2002, **129**:4635–4645.
7. Ahn DG, Kourakis MJ, Rohde LA, Silver LM, Ho RK: **T-box gene tbx5 is essential for formation of the pectoral limb bud.** *Nature* 2002, **417**:754–758.
8. Ghosh TK, Song FF, Packham EA, Buxton S, Robinson TE, Ronskley J, Self T, Bonser AJ, Brook JD: **Physical interaction between TBX5 and MEF2C is required for early heart development.** *Mol Cell Biol* 2009, **29**:2205–2218.
9. Lu JH, Lu JK, Choo SL, Li YC, Yeh HW, Shiu JF, Yeh VC: **Cascade effect of cardiac myogenesis gene expression during cardiac looping in tbx5 knockdown zebrafish embryos.** *J Biomed Sci* 2008, **15**:779–787.
10. Bruneau BG, Nemer G, Schmitt JP, Charron F, Robitaille L, Caron S, Conner DA, Gessler M, Nemer M, Seidman CE, Seidman JG: **A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease.** *Cell* 2001, **106**:709–721.
11. Hiroi Y, Kudoh S, Monzen K, Ikeda Y, Yazaki Y, Nagai R, Komuro I: **Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte differentiation.** *Nat Genet* 2001, **28**:276–280.
12. Maitra M, Schluterman MK, Nichols HA, Richardson JA, Lo CW, Srivastava D, Garg V: **Interaction of Gata4 and Gata6 with Tbx5 is critical for normal cardiac development.** *Dev Biol* 2009, **326**:368–377.
13. Goetz SC, Brown DD, Conlon FL: **TBX5 is required for embryonic cardiac cell cycle progression.** *Development* 2006, **133**:2575–2584.
14. Lu J, Tsai T, Choo S, Yeh S, Tang R, Yang A, Lee H, Lu J: **Induction of apoptosis and inhibition of cell growth by tbx5 knockdown contribute to dysmorphogenesis in Zebrafish embryos.** *J Biomed Sci* 2011, **18**:73–82.
15. Brown DD, Martz SN, Binder O, Goetz SC, Price BM, Smith JC, Conlon FL: **Tbx5 and Tbx20 act synergistically to control vertebrate heart morphogenesis.** *Development* 2005, **132**:553–563.
16. van den Eijnden MJ, Lahaye LL, Strous GJ: **Disulfide bonds determine growth hormone receptor folding, dimerisation and ligand binding.** *J Cell Sci* 2006, **119**:3078–3086.
17. Yada T, Azuma T, Takagi Y: **Stimulation of non-specific immune functions in seawater-acclimated rainbow trout, *Oncorhynchus mykiss*, with reference to the role of growth hormone.** *Comp Biochem Physiol B Biochem Mol Biol* 2001, **129**:695–701.
18. Rosa CE, Kuradomi RY, Almeida DV, Lannes CF: **Figueiredo Mde A, Dytz AG, Fonseca DB, Marins LF: GH overexpression modifies muscle expression of anti-oxidant enzymes and increases spinal curvature of old zebrafish.** *Exp Gerontol* 2010, **45**:449–456.
19. Dalla Libera L, Ravara B, Volterrani M, Gobbo V, Della Barbera M, Angelini A, Danieli Betto D, Germinario E, Vescovo G: **Beneficial effects of GH/IGF-1 on skeletal muscle atrophy and function in experimental heart failure.** *Am J Physiol Cell Physiol* 2004, **286**:C138–C144.
20. Gonzalez-Juanatey JR, Pineiro R, Iglesias MJ, Gualillo O, Kelly PA, Diéguez C, Lago F: **GH prevents apoptosis in cardiomyocytes cultured in vitro through a calcineurin-dependent mechanism.** *J Endocrinol* 2004, **180**:325–335.
21. Liu N, Mertani HC, Norstedt G, Tornell J, Lobie PE: **Mode of the autocrine/paracrine mechanism of growth hormone action.** *Exp Cell Res* 1997, **237**:196–206.
22. Pantaleon M, Whiteside EJ, Harvey MB, Barnard RT, Waters MJ, Kaye PL: **Functional growth hormone (GH) receptors and GH are expressed by preimplantation mouse embryos: a role for GH in early embryogenesis?** *Proc Natl Acad Sci USA* 1997, **94**:5125–5130.
23. Schulte-Merker S, Ho RK, Herrmann BG, Nusslein-Volhard C: **The protein product of the zebrafish homologue of the mouse T gene is expressed in nuclei of the germ ring and the notochord of the early embryo.** *Development* 1992, **116**:1021–1032.
24. Oxtoby E, Jowett T: **Cloning of the zebrafish krox-20 gene (krx-20) and its expression during hindbrain development.** *Nucleic Acids Res* 1993, **21**:1087–1095.
25. Hasson P, DeLaurier A, Bennett M, Grigorieva E, Naiche LA, Papaioannou VE, Mohun TJ, Logan MP: **Tbx4 and tbx5 acting in connective tissue are required for limb muscle and tendon patterning.** *Dev Cell* 2010, **18**:148–156.

26. Hatcher CJ, Kim MS, Mah CS, Goldstein MM, Wong B, Mikawa T, Basson CT: **TBX5 transcription factor regulates cell proliferation during cardiogenesis.** *Dev Biol* 2001, **230**:177–188.
27. Liberatore CM, Searcy-Schrick RD, Yutzey KE: **Ventricular expression of *tbx5* inhibits normal heart chamber development.** *Dev Biol* 2000, **223**:169–180.
28. Plageman TF Jr, Yutzey KE: **Differential expression and function of *Tbx5* and *Tbx20* in cardiac development.** *J Biol Chem* 2004, **279**:19026–19034.
29. Rothschild SC, Easley CA 4th, Francescatto L, Lister JA, Garrity DM, Tombs RM: **Tbx5-mediated expression of Ca(2+)/calmodulin-dependent protein kinase II is necessary for zebrafish cardiac and pectoral fin morphogenesis.** *Dev Biol* 2009, **330**:175–184.
30. Camarata T, Krcmery J, Snyder D, Park S, Topczewski J, Simon HG: **Pdlim7 (LMP4) regulation of *Tbx5* specifies zebrafish heart atrio-ventricular boundary and valve formation.** *Dev Biol* 2010, **337**:233–245.
31. Minguillon C, Gibson-Brown JJ, Logan MP: ***Tbx4/5* gene duplication and the origin of vertebrate paired appendages.** *Proc Natl Acad Sci USA* 2009, **106**:21726–21730.
32. Di Prinzio CM, Botta PE, Barriga EH, Rios EA, Reyes AE, Arranz SE: **Growth hormone receptors in zebrafish (*Danio rerio*): adult and embryonic expression patterns.** *Gene Expr Patterns* 2010, **10**:214–225.
33. Li X, He J, Hu W, Yin Z: **The essential role of endogenous ghrelin in growth hormone expression during zebrafish adenohypophysis development.** *Endocrinology* 2009, **150**:2767–2774.
34. Toro S, Wegner J, Muller M, Westerfield M, Varga ZM: **Identification of differentially expressed genes in the zebrafish hypothalamic-pituitary axis.** *Gene Expr Patterns* 2009, **9**:200–208.
35. Zhou J, Li W, Kamei H, Duan C: **Duplication of the IGFBP-2 gene in teleost fish: protein structure and functionality conservation and gene expression divergence.** *PLoS One* 2008, **3**:e3926.
36. Butler AA, Le Roith D: **Control of growth by the somatotropic axis: growth hormone and the insulin-like growth factors have related and independent roles.** *Annu Rev Physiol* 2001, **63**:141–164.
37. Ganong WF: **Review of medical physiology.** *Lange Medical Publications* 1981, **322**:table 22–23.
38. Xu Q: **Methods in Molecular Biology, Chapter 11 Microinjection into Zebrafish Embryos.** *Springer International Publisher* 1999, **127**:25–132.
39. Lincoln DT, Sinowatz F, Temmim-Baker L, Baker HI, Kölle S, Waters MJ: **Growth hormone receptor expression in the nucleus and cytoplasm of normal and neoplastic cells.** *Histochem Cell Biol* 1998, **109**:141–159.
40. Nadeau M, Georges RO, Laforest B, Yamak A, Lefebvre C, Beauregard J, Paradis P, Bruneau BG, Andelfinger G, Nemer M: **An endocardial pathway involving *Tbx5*, *Gata4*, and *Nos3* required for atrial septum formation.** *Proc Natl Acad Sci USA* 2010, **107**:19356–19361.
41. Eisenhauer KM, Chun SY, Billig H, Hsueh AJ: **Growth hormone suppression of apoptosis in preovulatory rat follicles and partial neutralization by insulin-like growth factor binding protein.** *Biol Reprod* 1995, **53**:13–20.
42. Stirnimann CU, Ptchelkine D, Grimm C, Muller CW: **Structural basis of TBX5-DNA recognition: the T-box domain in its DNA-bound and -unbound form.** *J Mol Biol* 2010, **400**:71–81.
43. Waters MJ, Shang CA, Behncken SN, Tam SP, Li H, Shen B, Lobie PE: **Growth hormone as a cytokine.** *Clin Exp Pharmacol Physiol* 1999, **26**:760–764.
44. Laz EV, Holloway MG, Chen CS, Waxman DJ: **Characterization of three growth hormone-responsive transcription factors preferentially expressed in adult female liver.** *Endocrinology* 2007, **148**:3327–3337.
45. Lomenick JP, Hubert MA, Handwerger S: **Transcription factor FOXF1 regulates growth hormone variant gene expression.** *Am J Physiol Endocrinol Metab* 2006, **291**:E947–951.
46. Snyder M, Huang XY, Zhang JJ: **Stat3 directly controls the expression of *Tbx5*, *Nkx2.5*, and *GATA4* and is essential for cardiomyocyte differentiation of P19CL6 cells.** *J Biol Chem* 2010, **285**:23639–23646.
47. Harvey S, Johnson CD, Sharma P, Sanders EJ, Hull KL: **Growth hormone: a paracrine growth factor in embryonic development?** *Comp Biochem Physiol C Pharmacol Toxicol Endocrinol* 1998, **119**:305–315.
48. Bruel A, Christoffersen TE, Nyengaard JR: **Growth hormone increases the proliferation of existing cardiac myocytes and the total number of cardiac myocytes in the rat heart.** *Cardiovasc Res* 2007, **76**:400–408.
49. DeBosch B, Sambandam N, Weinheimer C, Courtois M, Muslin AJ: **Akt2 regulates cardiac metabolism and cardiomyocyte survival.** *J Biol Chem* 2006, **281**:32841–32851.
50. Gabillard JC, Duval H, Cauty C, Rescan PY, Weil C: **Differential expression of the two GH genes during embryonic development of rainbow trout *Oncorhynchus mykiss* in relation with the IGFs system.** *Mol Reprod Dev* 2003, **64**:32–40.
51. Murakami Y, Shimizu T, Yamamoto M, Kato Y: **Serum levels of 20 kilodalton human growth hormone (20 K-hGH) in patients with acromegaly before and after treatment with octreotide and transsphenoidal surgery.** *Endocr J* 2004, **51**:343–348.
52. Harvey S, Johnson CD, Sanders EJ: **Extra-pituitary growth hormone in peripheral tissues of early chick embryos.** *J Endocrinol* 2000, **166**:489–502.
53. Joudrey EM, Lechniak D, Petrik J, King WA: **Expression of growth hormone and its transcription factor, Pit-1, in early bovine development.** *Mol Reprod* 2003, **64**:275–283.
54. Thatcher WW, Guzeloglu A, Meikle A, Kamimura S, Bilby T, Kowalski AA, Badinga L, Pershing R, Bartolome J, Santos JE: **Regulation of embryo survival in cattle.** *Reprod Suppl* 2003, **61**:253–266.

doi:10.1186/1423-0127-19-63

Cite this article as: Tsai et al.: The paracrine effect of exogenous growth hormone alleviates dysmorphogenesis caused by *tbx5* deficiency in zebrafish (*Danio rerio*) embryos. *Journal of Biomedical Science* 2012 **19**:63.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

